Related Experiment Video

Updated: Jul 15, 2025

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

266

MG53 does not mark cardiovascular risk and all-cause mortality in subjects with type 2 diabetes: A prospective,

Cristina Bianchi1, Olga Vaccaro2, Mariarosaria Distaso3

  • 1Department of Medical Specialties - Section of Metabolic Diseases and Diabetes, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

Diabetes Research and Clinical Practice
|September 25, 2023
PubMed
Abstract

Insights

In type 2 diabetes (T2D), MG53 levels are elevated but do not predict cardiovascular risk or mortality. This study found no link between MG53 and long-term outcomes in Caucasian T2D patients.

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Metabolic Syndrome

Background:

  • Type 2 diabetes (T2D) is associated with significant cardiovascular morbidity and mortality.
  • MG53, a marker of insulin resistance, is elevated in T2D and linked to beta-cell dysfunction.
  • The association between MG53 and cardiovascular risk or mortality in T2D remains unclear.

Purpose of the Study:

  • To investigate the relationship between circulating MG53 levels and the cardiovascular risk profile.
  • To determine if MG53 predicts all-cause mortality in Caucasian individuals with T2D.
  • To compare MG53 levels in T2D patients versus healthy individuals.

Main Methods:

  • A longitudinal study involving 296 Caucasian T2D participants from the MIND.IT study.
  • Serum MG53 levels were measured at baseline.
  • Follow-up was conducted over 17 years to assess cardiovascular risk and all-cause mortality.

Main Results:

  • MG53 levels were significantly higher in T2D individuals compared to healthy controls (p < 0.001).
  • T2D women exhibited higher MG53 levels than T2D men (p = 0.001).
  • MG53 levels correlated with HbA1c and systolic blood pressure but did not predict mortality.

Conclusions:

  • Circulating MG53 levels do not serve as a marker for cardiovascular risk profile in Caucasian T2D individuals.
  • MG53 does not predict long-term all-cause mortality in this population.
  • Further research may be needed to clarify the role of MG53 in T2D pathophysiology.
Keywords:
All-cause mortalityMG53Metabolic syndromeType 2 diabetes

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

650
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

220

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
110
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
20
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204